Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC 704865) in Advanced, Poor Prognosis Carcinoid Patients

Trial Profile

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC 704865) in Advanced, Poor Prognosis Carcinoid Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2b (Primary) ; Octreotide
  • Indications Carcinoid tumour; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms S0518
  • Most Recent Events

    • 02 Jun 2015 Primary endpoint has not been met. (Central-review based progression-free survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 27 Feb 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top